Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $20 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $20 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 24.2% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -395.4% | -455.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -411.3% | -465.9% |
| EPS Diluted | -3.33 | -0 | -1.12 | -1.02 |
| % Growth | -3,329,900% | 100% | -9.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |